European medical devices Report Interpretation

Overview

This report summarizes investor feedback following Morgan Stanley's European medical-technology initiations. The central split is between improving hearing-aid demand and selected execution-led rerating opportunities, versus earnings and guidance risks in refractive surgery, Coloplast and Smith+Nephew.

Core views

Morgan Stanley reports that investors are broadly constructive on hearing aids and increasingly prefer the sector to other areas of European MedTech. Its recovery thesis rests on incrementally positive market data over the prior two quarters and demographic analysis indicating long-run unit growth of 4%, versus a current 3% level. Recovering units and premiumisation in in-the-ear products could return market-value growth to roughly 5% over the next 12–18 months, although the timing of recovery is not yet fully de-risked. The firm believes ITE products could add more than 1 percentage point to market-value growth over the medium term and lift near-term value growth above 5% per year. Within hearing aids, Morgan Stanley reiterates Overweight on Demant and Equal-weight on Sonova. It sees Demant as having the clearer 12-month earnings-revision path because Zeal still has rollout runway and can support wider Oticon portfolio pull-through, gross-margin gains and sales-force efficiency. Morgan Stanley forecasts Demant gross margin at 77.7% in H2, rising to 78.1% in 2027E and 78.5% in 2028E. This implies 1.1 percentage points of EBIT-margin expansion versus 70 basis points in consensus and leaves its 2028E EPS about 3% above consensus. Sonova's Virto R and EON support above-market growth, but consensus already assumes Wholesale and Retail growth 2–3 percentage points above the market; Morgan Stanley therefore sees limited further incremental upside. A competitive instant-fit ITE launch, potentially as early as EUHA on 14–16 October 2026, is the main unmodeled Sonova upside catalyst, but remains optionality until launch timing and clinician adoption are confirmed. Morgan Stanley reiterates Overweight on Amplifon. The shares were down about 18% year to date and traded at roughly a 35% discount to their three-year forward P/E history, attracting investors who expect hearing-aid market recovery. Morgan Stanley expects Amplifon to be a major beneficiary through 2027 and estimates 2028E legacy-business net income about 3% above consensus, with €0.5–2.5 per share upside from the GN acquisition. It considers approximately 85% of GN synergies to come from lower-risk insourcing. However, the acquisition remains the principal obstacle to valuation recognition: investors are focused on customer churn, the move in sourcing from GN Hearing from about 40% to about 90%, integration complexity, R&D-staff retention and net-synergy delivery. Morgan Stanley also flags downside to consensus H1 2027 growth if prior performance benefited from internal revenue redistribution following store closures. For Carl Zeiss Meditec, Morgan Stanley reiterates Underweight. Channel checks indicate weak China refractive demand in August and recent company commentary has not indicated meaningful recovery. Weak China refractive and cataract volumes, soft global capital-equipment markets and back-end-loaded ProfitUp leave Morgan Stanley's FY2026/27E EBITA about 10% below consensus. Investors generally accept further earnings downside but think low liquidity, positioning and Zeiss AG share purchases may limit absolute share-price downside without a distinct negative catalyst. Morgan Stanley identifies ESCRS 2026 data and FY2025/26 results on 10 December 2026 as key potential catalysts for evidence of continuing refractive weakness or further EBITA cuts. Morgan Stanley reiterates Overweight on ConvaTec, where investors recognize strong execution but question the timing of a rerating after a prolonged period of delivery without material share-price progress. The report argues that ConvaTec could enter a higher-growth phase in 2027 and potentially close or surpass Coloplast's growth, ROIC and margin profile by 2028E. Consensus forecasts 6.9% revenue CAGR for 2026–28, within the company's 6–8% medium-term guidance, while Morgan Stanley sees growth visibility in Infusion Care and upcoming Wound and Ostomy launches. One-year Infusion Care order visibility, H2 margin recovery, further 2027 progress and roughly 100% through-cycle FCFE conversion put its 2028E EPS about 2.5% above consensus. Investors need to see visibility translate into reported growth, margin drop-through and cash returns before a rerating. For Coloplast, investors broadly expect a guidance reset because its 6–8% medium-term organic-growth target is viewed as ambitious amid Biologics and China headwinds, while 2027 faces raw-material, energy and HUF-cost pressure. Morgan Stanley sees a controlled reset to 5–7% growth and EBIT margin around 25% as most plausible, compared with Visible Alpha consensus revenue CAGR of 6.6% for 2026–28 and 26.2% EBIT margin expectations for 2026/27. A roughly 1 percentage point margin cut could imply low- to mid-single-digit EPS downside to consensus, while deeper cost and R&D requirements could imply high-single-digit downside. Morgan Stanley reiterates Equal-weight, judging that the substantial de-rating limits the case for greater caution, but warns that an insufficient reset could prolong the overhang and lead to additional downgrades. For Smith+Nephew, investors also expect a reset, with FY2026 guidance potentially addressed at Q3 results on 4 November and medium-term guidance at FY2026 results in February 2027. Consensus already assumes 3.6% 2026 revenue growth versus 4% guidance and 5.3% 2025–28 CAGR versus 6–7% guidance; at 11.5 times 2027 P/E, valuation is near five-year lows. Morgan Stanley believes the direction of a reset alone may have limited impact because much is reflected in estimates; the key is whether new operational and investment assumptions are achievable. Investors generally favor a 4–6% annual revenue-growth range and want evidence of delivery in US Orthopaedics. Morgan Stanley reiterates Equal-weight, with its 2028E EPS only about 2% below consensus.

Analysis framework

Morgan Stanley combines investor conversations with channel checks, market-growth evidence, demographic analysis, consensus comparisons and company-specific operating assumptions. It evaluates whether demand recovery, product launches, margin progression, cash conversion and guidance credibility can alter earnings expectations or valuation discounts over the next 12–18 months.

Methodology notes

• Industry AnalysisSupply-demand framework

  Hearing-aid market recovery analysis

  The report links unit demand, demographics and ITE premiumisation to a potential recovery in hearing-aid market-value growth toward about 5%.

• Industry AnalysisVolume-price decomposition

  Market-value growth from volume recovery and premiumisation

  Morgan Stanley separates the effect of recovering unit demand from higher-value product mix, particularly ITE devices, in explaining sector growth.

• Valuation methodsP/E and PEG Valuation

  P/E multiple comparisons

  The report uses forward P/E discounts, premiums and potential multiple expansion to frame relative valuation and rerating potential.

• Corporate Fundamentals and FinanceFree cash flow analysis

  FCFE conversion

  For ConvaTec, Morgan Stanley uses expected through-cycle FCFE conversion as evidence that reported growth and margin delivery can support a rerating.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Demant A/S (DEMANT.CO)

  Preferred hearing-aid exposure with the clearer earnings-upgrade path.

  Strengths

  Zeal rollout, Oticon portfolio pull-through and expected gross-margin expansion.

  Weaknesses

  Requires sustained market recovery and Zeal momentum.

  Comparison

  Morgan Stanley sees a clearer 12-month revision path than Sonova.

  Risks

  Hearing-aid recovery may take longer than expected.

• Sonova Holding AG (SOON.S)

  Hearing-aid beneficiary with product-launch optionality.

  Strengths

  EON and Virto R support above-market growth; instant-fit ITE could be additional upside.

  Weaknesses

  Consensus already assumes growth materially above the market and difficult H2 comparisons limit incremental upside.

  Comparison

  Trades at about a 1x 2026E P/E premium to Demant.

  Risks

  ITE timing and clinician adoption remain unconfirmed.

• Amplifon SpA (AMPF.MI)

  Hearing-aid recovery beneficiary with GN-acquisition upside.

  Strengths

  Operational leverage to market recovery, Fit4Growth and estimated acquisition synergies.

  Weaknesses

  GN integration, sourcing concentration and staff retention remain unresolved.

  Comparison

  Valuation was about 35% below its three-year forward P/E history.

  Risks

  Customer churn, delayed synergies and potential distortion from shop-closure revenue redistribution.

• Carl Zeiss Meditec AG (AFXG.DE)

  Refractive-demand risk exposure.

  Strengths

  Parent Zeiss AG share purchases and liquidity dynamics may limit near-term absolute downside.

  Weaknesses

  Weak China refractive and cataract volumes, soft equipment markets and earnings risk.

  Comparison

  Morgan Stanley forecasts FY2026/27E EBITA about 10% below consensus.

  Risks

  Further EBITA cuts and continued weak refractive surgery volumes.

• ConvaTec Group PLC (CTEC.L)

  Execution-led rerating candidate.

  Strengths

  Infusion Care order visibility, growth potential, margin recovery and cash conversion.

  Weaknesses

  Investors remain uncertain about timing and resilience of higher growth and margins.

  Comparison

  Morgan Stanley sees a plausible path for ConvaTec to overtake Coloplast on growth, ROIC and margins by 2028E.

  Risks

  Inflation, delayed Infusion Care conversion and insufficient margin delivery.

• Coloplast A/S (COLOb.CO)

  Guidance-reset situation.

  Strengths

  Substantial de-rating may limit the case for greater caution.

  Weaknesses

  Growth and margin targets are seen as ambitious amid Biologics, China and cost headwinds.

  Comparison

  Morgan Stanley sees 5–7% growth and around 25% margin as a plausible controlled reset.

  Risks

  An insufficient reset could lead to further downgrades through 2027.

• Smith & Nephew PLC (SN.L)

  Guidance-reset and operational-delivery situation.

  Strengths

  Valuation near five-year lows and much of the anticipated reset appears reflected.

  Weaknesses

  Current growth targets are viewed as ambitious and Orthopaedics execution remains important.

  Comparison

  Morgan Stanley's 2028E EPS is only about 2% below consensus.

  Risks

  A reset without achievable operational assumptions or strategic action may not improve the setup.

Key data

• Hearing-aid market-value growthc.5%Morgan Stanley expects reversion toward this level over the next 12–18 months.
• Long-term hearing-aid unit growth4%Demographic analysis versus current growth of 3%.
• Demant 2028E EPS versus consensusc.3% above consensusSupported by Zeal mix, gross-margin expansion and Oticon portfolio pull-through.
• Amplifon GN-acquisition upside€0.5–2.5 per shareMorgan Stanley's estimated upside, with about 85% of synergies from lower-risk insourcing.
• Carl Zeiss Meditec FY2026/27E EBITA versus consensusc.10% below consensusReflects weak refractive and cataract volumes, soft equipment markets and back-end-loaded ProfitUp.
• ConvaTec 2028E EPS versus consensusc.2.5% above consensusBased on Infusion Care visibility, margin recovery and about 100% through-cycle FCFE conversion.
• Smith+Nephew 2027 P/E11.5xNear five-year lows, indicating that a meaningful part of the expected reset is already reflected.

Impact & implications

The report argues that hearing-aid recovery could support earnings upgrades for Demant and selected sector beneficiaries, but product launches and confirmation of demand recovery are needed to unlock further upside. Elsewhere, execution proof and credible rebasing of targets—not merely the announcement of cuts—are the key determinants of whether valuation discounts narrow.

Risks

• Hearing-aid recovery may be delayed despite improving recent market data.
• Sonova's potential instant-fit ITE launch may not occur on the anticipated timetable or gain clinician adoption.
• Amplifon's GN integration could face customer churn, talent-retention problems, higher costs or delayed synergies.
• Continued weak refractive surgery demand could drive further Carl Zeiss Meditec earnings cuts.
• Coloplast and Smith+Nephew could face prolonged overhangs if guidance resets are not sufficiently credible.

What to watch

• Evidence that hearing-aid market-value growth is recovering toward about 5%, along with Demant Zeal share gains and gross margin above 78%.
• Timing and market reception of a Sonova instant-fit ITE product launch.
• Amplifon's GN customer and market share, R&D-staff retention and delivery of net synergies.
• ESCRS 2026 data and Carl Zeiss Meditec FY2025/26 results on 10 December 2026.
• ConvaTec's conversion of Infusion Care visibility into growth, margin drop-through and cash returns.
• The depth and credibility of Coloplast and Smith+Nephew guidance resets, including US Orthopaedics execution at Smith+Nephew.